Alpha 2.0
Login Register
» Authors » Alex Befeler

Alex Befeler

Explore the profile of Alex Befeler including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 7
Citations 196
Followers 0
Related Specialties
Gastroenterology
Oncology
General Surgery
Top 10 Co-Authors
K Rajender Reddy
Ruchi Bhatia
Mindie H Nguyen
John Dombrowski
Jorge A Marrero
Sameer Gadani
Lewis R Roberts
Nishant Poddar
Sudhir Srivastava
Sravanthi Ravulapati
Published In
Gastroenterology
J Gastrointest Cancer
Hepatology
Clin Transplant
Affiliations
Soon will be listed here.
Recent Articles
1.
A Phase 3 Biomarker Validation of GALAD for the Detection of Hepatocellular Carcinoma in Cirrhosis
Marsh T, Parikh N, Roberts L, Schwartz M, Nguyen M, Befeler A, et al.
Gastroenterology . 2024 Sep; 168(2):316-326.e6. PMID: 39293548
Background & Aims: Better surveillance tests for hepatocellular carcinoma (HCC) are needed. The GALAD score (gender, age, α-fetoprotein [AFP] L3, AFP, and des-γ carboxyprothrombin) has been shown to have excellent...
2.
Outcomes of kidney, liver, and simultaneous liver and kidney transplants from hepatitis c infected donors to hepatitis c naïve recipients: A large single center experience
Elbeshbeshy H, Modi N, Patel T, Matthews I, Kampert T, Lee J, et al.
Clin Transplant . 2023 Oct; 38(1):e15161. PMID: 37842872
Background: With the introduction of direct-acting antiviral therapies (DAAs), the non-use rate of hepatitis C virus (HCV)-positive donor organs (D+) has decreased significantly. We present the donor, recipient, and transplant...
3.
Incidence and Risk Factors for Hepatocellular Carcinoma in Cirrhosis: The Multicenter Hepatocellular Carcinoma Early Detection Strategy (HEDS) Study
Reddy K, McLerran D, Marsh T, Parikh N, Roberts L, Schwartz M, et al.
Gastroenterology . 2023 Jul; 165(4):1053-1063.e6. PMID: 37429366
Background & Aims: Worldwide, hepatocellular carcinoma (HCC) is a common malignancy. We aimed to prospectively determine the incidence and risk factors of HCC in a U.S. Cohort: Methods: The multicenter...
4.
Correction to: Hepatocellular Carcinoma with Bone Metastases: Incidence, Prognostic Significance, and Management-Single-Center Experience
Bhatia R, Ravulapati S, Befeler A, Dombrowski J, Gadani S, Poddar N
J Gastrointest Cancer . 2017 Oct; 48(4):390. PMID: 28986755
The original version of this article unfortunately contained a mistake in the Author group section. Author first names and family names were interchanged.
5.
Hepatocellular Carcinoma with Bone Metastases: Incidence, Prognostic Significance, and Management-Single-Center Experience
Bhatia R, Ravulapati S, Befeler A, Dombrowski J, Gadani S, Poddar N
J Gastrointest Cancer . 2017 Sep; 48(4):321-325. PMID: 28891006
Background: Hepatocellular carcinoma (HCC) represents one of the most common causes of cancer-related deaths worldwide, with rising incidence in the USA. Bone metastases with HCC, in particular, have an extremely...
6.
Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study
Curry M, Forns X, Chung R, Terrault N, Brown Jr R, Fenkel J, et al.
Gastroenterology . 2014 Sep; 148(1):100-107.e1. PMID: 25261839
Background & Aims: Patients with detectable hepatitis C virus (HCV) RNA at the time of liver transplantation universally experience recurrent HCV infection. Antiviral treatment before transplantation can prevent HCV recurrence,...
7.
Bile acid changes after high-dose ursodeoxycholic acid treatment in primary sclerosing cholangitis: Relation to disease progression
Sinakos E, Marschall H, Kowdley K, Befeler A, Keach J, Lindor K
Hepatology . 2010 Jun; 52(1):197-203. PMID: 20564380
Unlabelled: High-dose (28-30 mg/kg/day) ursodeoxycholic acid (UDCA) treatment improves serum liver tests in patients with primary sclerosing cholangitis (PSC) but does not improve survival and is associated with increased rates...